文献速递胸部肿瘤

不可切除NSCLC患者放化疗后度伐利尤单抗进展后免疫治疗与单纯化疗的疗效比较

Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab.
PubMed 文献 · Eur J Cancer · 2025-02-11

这项多中心回顾性研究纳入197例放化疗后度伐利尤单抗治疗后进展的不可切除III期NSCLC患者,比较免疫检查点抑制剂为基础治疗与单纯化疗的疗效。免疫治疗组中位无进展生存期5.9个月 vs 化疗组4.9个月(HR 0.67),中位总生存期14.6个月 vs 8.9个月(HR 0.61)。在度伐利尤单抗治疗期间无进展生存期≥12个月的患者中,后续免疫治疗较化疗总生存期更长。

要点

  • 免疫治疗组中位PFS 5.9个月 vs 化疗组4.9个月(HR 0.67,95%CI 0.49-0.91,p=0.011)
  • 免疫治疗组中位OS 14.6个月 vs 化疗组8.9个月(HR 0.61,95%CI 0.43-0.86,p=0.005)
  • 度伐利尤单抗治疗PFS≥12个月者,后续免疫治疗中位OS 22.0个月 vs 化疗9.8个月(p=0.024)

核心结论

  • 在放化疗和度伐利尤单抗治疗后进展的患者中,疾病进展时免疫检查点抑制剂再治疗可能较单纯化疗提供总生存获益,尤其对于度伐利尤单抗治疗期间未进展的患者。

研究设计与样本

  • 多中心回顾性研究,在意大利、美国、以色列和荷兰的10个中心开展,连续纳入放化疗和度伐利尤单抗治疗后复发的NSCLC患者,共197例符合入选标准。

主要发现

  • 93例接受化疗(±抗VEGF),104例接受免疫检查点抑制剂为基础的治疗(±化疗)。
  • 免疫治疗组中位PFS为5.9个月(95%CI 4.3-7.6),化疗组为4.9个月(95%CI 3.9-5.8),p=0.011,HR 0.67(95%CI 0.49-0.91)。
  • 免疫治疗组中位OS为14.6个月(95%CI 9.9-19.4),化疗组为8.9个月(95%CI 7.4-10.4),p=0.005,HR 0.61(95%CI 0.43-0.86)。
  • 度伐利尤单抗治疗期间PFS≥12个月的患者中,后续免疫治疗组中位OS为22.0个月(95%CI 12.9-31.2),化疗组为9.8个月(95%CI 4.3-15.2),p=0.024。
  • 度伐利尤单抗治疗期间PFS<12个月的患者中,免疫治疗与化疗组OS无显著差异。

临床怎么用

  • 作者认为,对于放化疗和度伐利尤单抗治疗后进展且未在度伐利尤单抗治疗期间复发的患者,疾病进展时免疫检查点抑制剂再治疗可能较化疗提供总生存获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often necessitating subsequent systemic therapy. The only available data about re-challenge immune checkpoint blockers (ICB) in this setting derives from small retrospective series. We evaluated progression free survival (PFS) and overall survival (OS) in patients receiving either ICB-based therapy versus a chemotherapy (CT)-only for disease progression after CRT and durvalumab. MATERIALS AND METHODS: Multicenter retrospective study, conducted across 10 centers in Italy, the USA, Israel, and The Netherlands. Consecutive patients with relapsed NSCLC following CRT and durvalumab were enrolled. RESULTS: A total of 197 patients met the eligibility criteria: 93 received CT ( ± anti-VEGF), and 104 received an ICB-based treatment ( ± CT). The median PFS for patients receiving an ICB-based versus a CT-only regimen was 5.9 (95 % CI 4.3-7.6) versus 4.9 months (95 % CI 3.9-5.8), respectively (p = 0.011, HR: 0.67, 95 % CI 0.49-0.91). The median OS was 14.6 months (95 % CI 9.9-19.4) versus 8.9 (95 % CI 7.4-10.4), respectively (p = 0.005, HR: 0.61, 95 % CI 0.43-0.86). Patients with PFS ≥ 12 months on durvalumab, treated with subsequent ICB or CT median OS was 22.0 (95 % CI: 12.9-31.2) 9.8 months (95 % CI: 4.3-15.2) respectively (p = 0.024). Among patients with a PFS < 12 months on durvalumab there was no significant OS difference between ICB and CT arms. CONCLUSIONS: ICB retreatment at disease progression after CRT and durvalumab might offer an OS benefit over CT in patients who do not relapse during durvalumab treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cortiula F, Kutiel TS, Hsu ML, et al. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab. Eur J Cancer. 2025. PMID: 39987799. doi:10.1016/j.ejca.2025.115302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。